

Reninâ€™Angiotensinâ€™Aldosterone System Inhibitors

New England Journal of Medicine

382, 2441-2448

DOI: [10.1056/nejmoa2008975](https://doi.org/10.1056/nejmoa2008975)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2. Archives of Cardiovascular Diseases, 2020, 113, 572-578.	0.7	2
3	The Controversy of Renin-angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection. Journal of Cardiovascular Pharmacology, 2020, 76, 397-406.	0.8	16
4	Cardiovascular disease and cardiovascular outcomes in COVID-19. Practical Diabetes, 2020, 37, 191.	0.1	7
5	Coronavirus and Cardiometabolic Syndrome. Journal of the American College of Cardiology, 2020, 76, 2024-2035.	1.2	38
6	Coronavirus disease 2019 (COVID-19) and obesity. Impact of obesity and its main comorbidities in the evolution of the disease. European Eating Disorders Review, 2020, 28, 799-815.	2.3	22
7	SARS-CoV-2: recommendations for treatment in intensive care medicine. Wiener Klinische Wochenschrift, 2020, 132, 664-670.	1.0	8
8	Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. Clinical and Experimental Allergy, 2020, 50, 1313-1324.	1.4	69
9	COVID-19 and Respiratory System Disorders. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2586-2597.	1.1	110
10	Acute Kidney Injury in COVID-19: The Chinese Experience. Seminars in Nephrology, 2020, 40, 430-442.	0.6	27
11	Perioperative Nonsteroidal Anti-Inflammatory Agents in the COVID-19 Orthopedic Patient. HSS Journal, 2020, 16, 97-101.	0.7	1
12	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. Frontiers in Pharmacology, 2020, 11, 1224.	1.6	30
13	Different Laboratory Abnormalities in COVID-19 Patients with Hypertension or Diabetes. Virologica Sinica, 2020, 35, 853-856.	1.2	1
14	SARS-CoV-2-Related Kidney Injury: Current Concern and Challenges. SN Comprehensive Clinical Medicine, 2020, 2, 2015-2024.	0.3	5
15	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?. Pharmacology Research and Perspectives, 2020, 8, e00666.	1.1	18
16	The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. Drugs and Aging, 2020, 37, 779-785.	1.3	9
17	Lessons from COVID-19: How human behaviour may influence the science. Diabetes Research and Clinical Practice, 2020, 169, 108491.	1.1	3
18	Strategies and Advances in Combating COVID-19 in China. Engineering, 2020, 6, 1076-1084.	3.2	16
19	Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis, 2020, 314, 58-62.	0.4	213

#	ARTICLE	IF	CITATIONS
20	Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis. <i>PLoS Computational Biology</i> , 2020, 16, e1008235.	1.5	11
21	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO). <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 585866.	1.1	63
22	Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2011-2023.	1.2	165
23	Vascular Events, Vascular Disease and Vascular Risk Factorsâ€”Strongly Intertwined with COVID-19. <i>Current Treatment Options in Neurology</i> , 2020, 22, 40.	0.7	10
24	Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. <i>Atherosclerosis</i> , 2020, 313, 126-136.	0.4	52
25	Novel coronavirus disease in patients with endâ€”stage kidney disease. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 25, 544-550.	0.4	9
26	SARS-CoV-2 receptor networks in diabetic and COVID-19â€”associated kidney disease. <i>Kidney International</i> , 2020, 98, 1502-1518.	2.6	64
27	COVID-19 Genetic and Environmental Risk Factors: A Look at the Evidence. <i>Frontiers in Pharmacology</i> , 2020, 11, 579415.	1.6	15
28	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>European Journal of Cancer</i> , 2020, 140, 86-104.	1.3	33
29	Management of Comedication in Hospitalized COVID-19 Patients With Atrial Fibrillation. <i>Hospital Pharmacy</i> , 2021, 56, 629-632.	0.4	0
30	Angiotensinâ€”converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensinâ€”converting enzyme 2 in patients with cardiovascular disease. <i>European Journal of Heart Failure</i> , 2020, 22, 2248-2257.	2.9	13
31	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 703-714.	2.6	36
33	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. <i>Nature Reviews Cardiology</i> , 2020, 17, 543-558.	6.1	999
34	<scp>COVID</scp> â€”19 outbreak and pediatric diabetes: Perceptions of health care professionals worldwide. <i>Pediatric Diabetes</i> , 2020, 21, 1083-1092.	1.2	92
35	Pharmaco-Immunomodulatory Therapy in COVID-19. <i>Drugs</i> , 2020, 80, 1267-1292.	4.9	208
36	Issues for the management of people with diabetes and COVID-19 in ICU. <i>Cardiovascular Diabetology</i> , 2020, 19, 114.	2.7	41
37	Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1623-1630.	0.8	81
38	The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 321-327.	1.8	114

#	ARTICLE	IF	CITATIONS
39	Immune-mediated approaches against COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 630-645.	15.6	260
40	Covid-19, ACE2 and the kidney. <i>Acta Physiologica</i> , 2020, 230, e13539.	1.8	29
41	Metabolic Syndrome and Viral Pathogenesis: Lessons from Influenza and Coronaviruses. <i>Journal of Virology</i> , 2020, 94, .	1.5	40
42	Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis. <i>Frontiers in Immunology</i> , 2020, 11, 1472.	2.2	38
43	Will children reveal their secret? The coronavirus dilemma. <i>European Respiratory Journal</i> , 2020, 55, 2001617.	3.1	70
44	Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic. <i>BMC Medicine</i> , 2020, 18, 220.	2.3	78
45	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. <i>Life Sciences</i> , 2020, 257, 118075.	2.0	87
46	ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities – Role of gut microbiota dysbiosis. <i>Ageing Research Reviews</i> , 2020, 62, 101123.	5.0	118
47	Comment on: COVID-19 and Older Adults: What We Know. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2197-2197.	1.3	2
48	State-of-the-Art review: Hypertension practice guidelines in the era of COVID-19. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100038.	1.3	15
49	SARS-CoV-2 and the cardiovascular system. <i>Clinica Chimica Acta</i> , 2020, 510, 311-316.	0.5	11
50	COVID-19 in people with diabetes: understanding the reasons for worse outcomes. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 782-792.	5.5	668
51	Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea. <i>Hypertension</i> , 2020, 76, 742-749.	1.3	33
53	Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1103-1108.	0.3	15
54	Potential Roles of the Renin-Angiotensin System in the Pathogenesis and Treatment of COVID-19. <i>BioMed Research International</i> , 2020, 2020, 1-7.	0.9	2
55	Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 593061.	1.1	3
56	Biological Context Linking Hypertension and Higher Risk for COVID-19 Severity. <i>Frontiers in Physiology</i> , 2020, 11, 599729.	1.3	9
57	COVID-19 and inhibitors of the renin-angiotensin-aldosterone system. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 815-816.	2.0	3

#	ARTICLE	IF	CITATIONS
58	Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review. <i>Porto Biomedical Journal</i> , 2020, 5, e085.	0.4	12
59	Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 473-481.	0.1	9
60	COVID-19 and cardiovascular diseases. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 161-167.	1.5	17
61	Possible Correlations between Atherosclerosis, Acute Coronary Syndromes and COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3746.	1.0	23
62	COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial. <i>Cardiovascular Research</i> , 2020, 116, e198-e199.	1.8	13
63	Management of Canadian Pediatric Patients With Glomerular Diseases During the COVID-19 Pandemic: Recommendations From the Canadian Association of Pediatric Nephrologists COVID-19 Rapid Response Team. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812097071.	0.6	5
64	Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa519.	0.4	7
66	Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults. <i>Annals of Internal Medicine</i> , 2020, 173, 195-203.	2.0	113
67	Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System. <i>Viruses</i> , 2020, 12, 1367.	1.5	15
68	A Novel Angiotensin Converting Enzyme 2 (ACE2) Activating Peptide: A Reflection of 10 Years of Research on a Small Peptide Ile-Arg-Trp (IRW). <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 14402-14408.	2.4	13
69	Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study. <i>Cardiovascular Diabetology</i> , 2020, 19, 205.	2.7	103
70	Renin-angiotensin system blockers and the risk of critical or fatal coronavirus disease 2019 in African Americans. <i>Journal of Hypertension</i> , 2020, 38, 2384-2386.	0.3	1
71	SARS-CoV-2 receptor is co-expressed with elements of the kinin-kallikrein, renin-angiotensin and coagulation systems in alveolar cells. <i>Scientific Reports</i> , 2020, 10, 19522.	1.6	39
72	Patients taking angiotensin-converting enzyme inhibitors/angiotensin II type I receptor blockers: higher risks of severe acute respiratory syndrome coronavirus 2 infection but milder clinical manifestations?. <i>Chinese Medical Journal</i> , 2020, 133, 2650-2652.	0.9	2
73	Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis. <i>Internal Medicine Journal</i> , 2020, 50, 1468-1474.	0.5	15
74	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. <i>Clinical Cardiology</i> , 2020, .	0.7	58
75	Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1244-1252.	0.7	45
76	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. <i>EBioMedicine</i> , 2020, 58, 102907.	2.7	110

#	ARTICLE	IF	CITATIONS
77	Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2020, 56, 112-115.	0.2	1
78	The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. <i>Cells</i> , 2020, 9, 1704.	1.8	32
79	The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2315.	1.0	33
80	Increased mortality among hypertensive COVID-19 patients: Pay a closer look on diuretics in mechanically ventilated patients. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 894-895.	0.8	8
81	Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety. <i>Journal of Drug Targeting</i> , 2020, 28, 683-699.	2.1	26
82	Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome. <i>Journal of Infectious Diseases</i> , 2020, 222, 1256-1264.	1.9	91
83	COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Canadian Pharmacists Journal</i> , 2020, 153, 193-197.	0.4	2
84	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5224.	1.8	42
85	<p>COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients</p>. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 1231-1240.	1.3	25
86	COVID-19 and the Kidneys: An Update. <i>Frontiers in Medicine</i> , 2020, 7, 423.	1.2	79
87	Sacubitril, valsartan and SARS-CoV-2. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 205-205.	1.7	29
88	Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 475-485.	0.6	4
89	Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. <i>Hypertension Research</i> , 2020, 43, 1028-1046.	1.5	131
90	Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?. <i>International Journal of Cardiology</i> , 2020, 321, 150-154.	0.8	12
91	Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. <i>Cardiovascular Research</i> , 2020, 116, 2177-2184.	1.8	331
92	Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6842-6851.	2.0	43
93	Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population. <i>Archives of Gerontology and Geriatrics</i> , 2020, 91, 104204.	1.4	41
94	Treatment impact on COVID-19 evolution in hemodialysis patients. <i>Kidney International</i> , 2020, 98, 1053-1054.	2.6	14

#	ARTICLE	IF	CITATIONS
95	Myocardial Injury in COVID-19 Patients. <i>Journal of the American College of Cardiology</i> , 2020, 76, 547-549.	1.2	10
96	The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. <i>Life Sciences</i> , 2020, 257, 118142.	2.0	14
97	Análisis de la relación entre los inhibidores del sistema renina-angiotensina y la evolución de pacientes hospitalizados por infección respiratoria COVID-19. <i>Medicina Clínica</i> , 2020, 155, 473-481.	0.3	7
98	COVID-19: a novel menace for the practice of nephrology and how to manage it with minor devastation?. <i>Renal Failure</i> , 2020, 42, 710-725.	0.8	13
99	Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1379-1388.	1.0	35
100	Cardio-Oncology in the Era of the COVID-19 Pandemic and Beyond. <i>Journal of the American Heart Association</i> , 2020, 9, e017787.	1.6	23
101	Commentary on: "Does COVID-19 Infect the Brain? If So, Smokers Might Be at a Higher Risk". <i>Molecular Pharmacology</i> , 2020, 98, 382-383.	1.0	3
102	Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors. <i>European Journal of Anaesthesiology</i> , 2020, 37, 739-742.	0.7	2
103	Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity. <i>Obesity Facts</i> , 2020, 13, 439-452.	1.6	49
104	Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 630-633.	0.6	13
105	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. <i>Journal of Clinical Medicine</i> , 2020, 9, 2542.	1.0	2
106	<p>>Approaches to the Management of Hypertension in Resource-Limited Settings: Strategies to Overcome the Hypertension Crisis in the Post-COVID Era<p>>. <i>Integrated Blood Pressure Control</i> , 2020, Volume 13, 125-133.	0.4	16
107	Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3472.	1.0	6
108	ACE2 contributes to the maintenance of mouse epithelial barrier function. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 1276-1282.	1.0	27
109	Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. <i>BMJ Open</i> , 2020, 10, e043651.	0.8	69
110	Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. <i>IJC Heart and Vasculature</i> , 2020, 31, 100627.	0.6	29
111	The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. <i>BMC Nephrology</i> , 2020, 21, 449.	0.8	61
112	RAAS Inhibitors and Risk of Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1990-1994.	13.9	21

#	ARTICLE	IF	CITATIONS
113	Emergency Department Management of COVID-19: An Evidence-Based Approach. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 32-44.	0.6	3
114	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. <i>Cell Discovery</i> , 2020, 6, 77.	3.1	54
115	The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. <i>IJC Heart and Vasculature</i> , 2020, 31, 100660.	0.6	25
116	ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. <i>Nature Communications</i> , 2020, 11, 5453.	5.8	191
117	Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1629-1641.	1.8	44
118	Intricate interplay between Covid-19 and cardiovascular diseases. <i>Reviews in Medical Virology</i> , 2020, 31, e2188.	3.9	9
119	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 797-810.	0.7	7
120	Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. <i>Journal of NeuroVirology</i> , 2020, 26, 631-641.	1.0	38
121	Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients. <i>BMC Medical Research Methodology</i> , 2020, 20, 220.	1.4	6
122	Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Hypertension</i> , 2020, 76, 1563-1571.	1.3	36
123	Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 75.	1.2	221
124	Is Sex a Determinant of COVID-19 Infection? Truth or Myth?. <i>Current Hypertension Reports</i> , 2020, 22, 62.	1.5	18
125	Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1185-1194.	2.3	49
126	Cardiovascular Changes in Patients With COVID-19 From Wuhan, China. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 150.	1.1	9
127	Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study. <i>Pathogens</i> , 2020, 9, 759.	1.2	46
128	Predictors at Admission of Mechanical Ventilation and Death in an Observational Cohort of Adults Hospitalized With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e4141-e4151.	2.9	28
129	Artificial intelligence in COVID-19 drug repurposing. <i>The Lancet Digital Health</i> , 2020, 2, e667-e676.	5.9	349
130	Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. <i>American Journal of Cardiology</i> , 2020, 136, 149-155.	0.7	134

#	ARTICLE	IF	CITATIONS
131	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6790.	1.8	52
132	Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients. <i>Current Atherosclerosis Reports</i> , 2020, 22, 61.	2.0	78
133	CSANZ Position Statement on COVID-19 From the Paediatric and Congenital Council. <i>Heart Lung and Circulation</i> , 2020, 29, e217-e221.	0.2	4
134	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 143.	1.1	35
135	Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 148, 25-33.	0.9	26
136	COVID-19 and renin-angiotensin system modulators: what do we know so far?. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 743-748.	0.6	9
137	Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. <i>European Journal of Heart Failure</i> , 2020, 22, 2205-2215.	2.9	173
138	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor. <i>Hypertension</i> , 2020, 76, 1339-1349.	1.3	147
139	What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?. <i>Hypertension</i> , 2020, 76, 665-669.	1.3	3
140	Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System. <i>Hypertension</i> , 2020, 76, e34-e36.	1.3	57
141	Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?. <i>Frontiers in Immunology</i> , 2020, 11, 2014.	2.2	48
142	Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. <i>Drug Safety</i> , 2020, 43, 1297-1308.	1.4	48
143	Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 790-798.	1.5	211
144	Is diabetes mellitus a risk factor for Coronavirus Disease 19 (COVID-19)?. <i>Acta Diabetologica</i> , 2020, 57, 1275-1285.	1.2	50
145	Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19. <i>Genes</i> , 2020, 11, 1044.	1.0	52
146	Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. <i>American Journal of Hypertension</i> , 2020, 33, 1102-1111.	1.0	37
147	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. <i>Current Hypertension Reports</i> , 2020, 22, 90.	1.5	35
148	Smoking and COVID-19: Adding Fuel to the Flame. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6581.	1.8	76

#	ARTICLE	IF	CITATIONS
149	ACE polymorphisms and COVID-19-related mortality in Europe. <i>Journal of Molecular Medicine</i> , 2020, 98, 1505-1509.	1.7	32
150	Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. <i>ESC Heart Failure</i> , 2020, 7, 3464-3472.	1.4	19
151	Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 919-930.	0.6	25
152	Pharmacological rationale for antihypertensive drug choice on COVID-19-affected patients: ACEI/ARB might not increase their susceptibility. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12879-12881.	1.6	1
153	Relating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID-19. <i>ESC Heart Failure</i> , 2020, 7, 3119-3123.	1.4	3
154	Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003308.	3.9	76
155	Renin-Angiotensin System Blockade in Aortic Stenosis: Implications Before and After Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2020, 9, e016911.	1.6	23
156	Dendritic Cells and SARS-CoV-2 Infection: Still an Unclarified Connection. <i>Cells</i> , 2020, 9, 2046.	1.8	46
157	COVID-19 Usurps Host Regulatory Networks. <i>Frontiers in Pharmacology</i> , 2020, 11, 1278.	1.6	27
158	Mortality and Pre-Hospitalization Use of Renin-Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID-19). <i>Journal of the American Heart Association</i> , 2020, 9, e017736.	1.6	24
159	Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders. <i>Frontiers in Medicine</i> , 2020, 7, 515.	1.2	7
160	Collider bias undermines our understanding of COVID-19 disease risk and severity. <i>Nature Communications</i> , 2020, 11, 5749.	5.8	605
161	Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. <i>Scientific Reports</i> , 2020, 10, 20250.	1.6	18
162	Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. <i>Journal of International Medical Research</i> , 2020, 48, 030006052097915.	0.4	16
163	Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 4021.	1.0	13
164	Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032032097909.	1.0	5
165	Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension. <i>Frontiers in Immunology</i> , 2020, 11, 596684.	2.2	20
166	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020, 33, 177-189.	0.3	2

#	ARTICLE	IF	CITATIONS
167	Effects of ACEI and ARB on COVID-19 patients: A meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2020, 21, 147032032098132.	1.0	16
168	Clinical Characteristics and Immune Responses of 137 Deceased Patients With COVID-19: A Retrospective Study. Frontiers in Cellular and Infection Microbiology, 2020, 10, 595333.	1.8	16
169	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. Frontiers in Cardiovascular Medicine, 2020, 7, 568720.	1.1	5
170	Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection. Kidney360, 2020, 1, 801-809.	0.9	23
171	Update on COVID-19 Myocarditis. Medicina (Lithuania), 2020, 56, 678.	0.8	41
172	Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19. Mayo Clinic Proceedings, 2020, 95, 2559-2561.	1.4	5
173	The significance of hyperglycaemia and other comorbidities during the COVID-19 pandemic. Practical Diabetes, 2020, 37, 157-169.	0.1	0
174	Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812096895.	0.6	4
175	Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. Medicina Clínica (English Edition), 2020, 155, 488-490.	0.1	6
176	Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. BMJ Open, 2020, 10, e041577.	0.8	29
177	SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle. International Journal of Molecular Sciences, 2020, 21, 7904.	1.8	22
178	The outcomes of the postulated interaction between SARS-CoV-2 and the renin-angiotensin system on the clinician's attitudes toward hypertension treatment. Journal of Human Hypertension, 2020, 35, 828-836.	1.0	1
179	SARS-CoV-2 (COVID-19) and the Endocrine System. Journal of the Endocrine Society, 2020, 4, bvaa144.	0.1	40
180	Interim Guidance on the Preparticipation Physical Examination for Athletes During the SARS-CoV-2 Pandemic. Current Sports Medicine Reports, 2020, 19, 498-503.	0.5	0
181	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Frontiers in Pharmacology, 2020, 11, 588654.	1.6	99
182	Delay, Death, and Heterogeneity of Primary PCI During the COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 76, 2331-2333.	1.2	11
183	Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 157-164.	1.4	64
184	COVID-19 Awareness Among Dental Professionals in Indonesia. Frontiers in Medicine, 2020, 7, 589759.	1.2	11

#	ARTICLE	IF	CITATIONS
185	Emerging cardiological issues during the COVID-19 pandemic. European Journal of Clinical Investigation, 2020, 50, e13270.	1.7	11
186	Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19. Lancet, The, 2020, 395, 1671-1673.	6.3	43
187	ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Pharmacological Research, 2020, 158, 104927.	3.1	143
188	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. Vaccines, 2020, 8, 224.	2.1	47
189	The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Internal and Emergency Medicine, 2020, 15, 759-766.	1.0	118
190	Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. Journal of Clinical Medicine, 2020, 9, 1417.	1.0	411
191	Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 exploring RAS inhibitors. Alimentary Pharmacology and Therapeutics, 2020, 52, 569-570.	1.9	14
192	Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. Journal of Infection, 2020, 81, 276-281.	1.7	73
194	COVID-19. Hypertension, 2020, 76, 294-299.	1.3	64
195	Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. European Journal of Heart Failure, 2020, 22, 967-974.	2.9	163
196	Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.. New England Journal of Medicine, 2020, 382, 2464-2464.	13.9	27
197	Does type of immunosuppression influence the course of Covid-19 infection?. Journal of Infection, 2020, 81, e132-e135.	1.7	13
198	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?. Pharmacological Research, 2020, 158, 104906.	3.1	72
199	COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. European Journal of Heart Failure, 2020, 22, 957-966.	2.9	208
200	COVID-19 in diabetic patients: Related risks and specifics of management. Annales D'Endocrinologie, 2020, 81, 101-109.	0.6	65
201	Is the kidney a target of SARS-CoV-2?. American Journal of Physiology - Renal Physiology, 2020, 318, F1454-F1462.	1.3	159
202	Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Diseases and Translational Medicine, 2020, 6, 98-105.	0.9	34
203	Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective. Canadian Journal of Cardiology, 2020, 36, 1068-1080.	0.8	141

#	ARTICLE	IF	CITATIONS
205	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1034-1042.	4.6	493
206	Covid-19 and cardiovascular disease. <i>BMJ</i> , The, 2020, 369, m1997.	3.0	16
207	Evidence That Renin-Angiotensin System Inhibitors Should Not Be Discontinued Due to the COVID-19 Pandemic. <i>Hypertension</i> , 2020, 76, 42-43.	1.3	7
208	A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 954-975.	1.0	14
209	<scp>COVID</scp>-19: a brief history and treatments in development. <i>The Prescriber</i> , 2020, 31, 23-28.	0.1	35
210	COVID-19 – Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?. <i>Heart Lung and Circulation</i> , 2020, 29, 964-972.	0.2	25
212	Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 381-395.	0.4	43
213	Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?. <i>Current Hypertension Reports</i> , 2020, 22, 43.	1.5	37
214	Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China. <i>Journal of Medical Virology</i> , 2020, 92, 2821-2829.	2.5	41
215	Age and Multimorbidity Predict Death Among COVID-19 Patients. <i>Hypertension</i> , 2020, 76, 366-372.	1.3	330
216	The Impact of the COVID-19 – Infodemic – on Drug-Utilization Behaviors: Implications for Pharmacovigilance. <i>Drug Safety</i> , 2020, 43, 699-709.	1.4	56
217	Association between angiotensin blockade and COVID-19 severity in Hong Kong. <i>Cmaj</i> , 2020, 192, E635-E635.	0.9	7
218	Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling. <i>Frontiers in Pharmacology</i> , 2020, 11, 836.	1.6	47
219	COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1053-1060.	1.8	36
220	Considerations for Heart Failure Care During the COVID-19 Pandemic. <i>JACC: Heart Failure</i> , 2020, 8, 681-691.	1.9	89
221	COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?. <i>Heart</i> , 2020, 106, 1127-1131.	1.2	172
222	A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. <i>American Journal of Cardiology</i> , 2020, 130, 159-161.	0.7	23
223	Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?. <i>Pharmacological Research</i> , 2020, 159, 104959.	3.1	4

#	ARTICLE	IF	CITATIONS
224	Antihypertensive drugs in COVID-19 infection. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 415-416.	1.4	24
225	Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. <i>European Heart Journal</i> , 2020, 41, 2067-2069.	1.0	13
226	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	1.4	97
227	Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19. <i>Cells</i> , 2020, 9, 1383.	1.8	220
228	Potential role of statins in COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 96, 615-617.	1.5	85
229	Approach to Acute Cardiovascular Complications in COVID-19 Infection. <i>Circulation: Heart Failure</i> , 2020, 13, e007220.	1.6	94
230	Heart failure in the course of a pandemic. <i>European Journal of Heart Failure</i> , 2020, 22, 1755-1758.	2.9	5
232	Perspectives on Cardiopulmonary Critical Care for Patients With COVID-19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. <i>Journal of the American Heart Association</i> , 2020, 9, e017111.	1.6	5
233	Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 168.	3.8	331
234	Clinical Characteristics and Outcomes of Community- and Hospital-Acquired Acute Kidney Injury with COVID-19 in a US Inner City Hospital System. <i>CardioRenal Medicine</i> , 2020, 10, 223-231.	0.7	65
235	Angiotensin II administration to COVID-19 patients is not advisable. <i>Critical Care</i> , 2020, 24, 296.	2.5	9
236	Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1227-1235.	1.1	29
237	COVID-19: from epidemiology to treatment. <i>European Heart Journal</i> , 2020, 41, 2092-2112.	1.0	67
238	Renin-angiotensin system inhibition in COVID-19 patients. <i>Netherlands Heart Journal</i> , 2020, 28, 396-405.	0.3	15
239	Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives. <i>American Journal of Hypertension</i> , 2020, 33, 944-948.	1.0	72
240	Acute kidney injury in critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 1339-1348.	3.9	385
241	Does Ibuprofen Worsen COVID-19?. <i>Drug Safety</i> , 2020, 43, 611-614.	1.4	66
242	Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. <i>Journal of the American College of Cardiology</i> , 2020, 76, 533-546.	1.2	592

#	ARTICLE	IF	CITATIONS
243	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. <i>European Respiratory Journal</i> , 2020, 56, 2001634.	3.1	284
244	The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?. <i>Acta Clinica Belgica</i> , 2020, , 1-8.	0.5	10
245	Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. <i>Medicina Clínica</i> , 2020, 155, 488-490.	0.3	13
246	Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course. <i>Endocrinology</i> , 2020, 161, .	1.4	80
247	SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. <i>Theranostics</i> , 2020, 10, 7448-7464.	4.6	180
248	The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 983-990.	1.8	78
249	Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. <i>Heart</i> , 2020, 106, 1519-1524.	1.2	83
251	Renin-Angiotensin System Blockade in COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 277-279.	1.2	7
252	Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L325-L336.	1.3	69
253	Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232093576.	1.1	133
254	COVID-19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1109-1119.	1.0	45
256	COVID-19 and the Renin Angiotensin System: Implications for the Older Adults. <i>Journal of Nutrition, Health and Aging</i> , 2020, 24, 699-704.	1.5	21
259	In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1553-1556.	1.4	3
260	COVID-19: From pathogenesis models to the first drug trials. <i>Microbial Biotechnology</i> , 2020, 13, 1289-1299.	2.0	2
261	Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. <i>PLoS ONE</i> , 2020, 15, e0235248.	1.1	71
262	Comorbid Medical Conditions in Young Athletes: Considerations for Preparticipation Guidance During the COVID-19 Pandemic. <i>Sports Health</i> , 2020, 12, 456-458.	1.3	8
263	SARS-CoV-2 pandemic: An overview. <i>Advances in Biological Regulation</i> , 2020, 77, 100736.	1.4	65
264	Susceptibility and prognosis of COVID-19 patients with cardiovascular disease. <i>Open Heart</i> , 2020, 7, e001310.	0.9	8

#	ARTICLE	IF	CITATIONS
265	Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19. <i>Cmaj</i> , 2020, 192, E611-E611.	0.9	1
266	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300
267	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. <i>Frontiers of Medicine</i> , 2020, 14, 601-612.	1.5	38
268	Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 404-411.	0.6	13
269	Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Use and COVID-19: Time to Change Practice or Keep Gathering Data?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2457-2458.	2.9	1
270	COVID-19 and arterial hypertension: Hypothesis or evidence?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1120-1126.	1.0	65
271	Molecular Aspects of COVID-19 Differential Pathogenesis. <i>Pathogens</i> , 2020, 9, 538.	1.2	18
272	Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature. <i>Advances in Therapy</i> , 2020, 37, 3450-3462.	1.3	6
273	Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 2462-2464.	13.9	107
274	A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 148-157.	1.4	72
275	Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 76-77.	1.4	19
276	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. <i>Journal of Cardiology</i> , 2021, 77, 482-491.	0.8	49
277	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. <i>Vascular</i> , 2021, 29, 220-227.	0.4	1
278	Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. <i>Gut</i> , 2021, 70, 76-84.	6.1	167
280	Covid-19 and the cardiovascular system: a comprehensive review. <i>Journal of Human Hypertension</i> , 2021, 35, 4-11.	1.0	238
281	Discordant courses of COVID-19 in a cohabiting couple of lung transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13410.	0.7	5
282	The impact of the global COVID-19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 837-844.	1.1	12
283	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 249-259.	1.3	33

#	ARTICLE	IF	CITATIONS
284	Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. <i>Inflammation</i> , 2021, 44, 13-34.	1.7	162
285	Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: Meta-analysis. <i>Journal of Medical Virology</i> , 2021, 93, 2084-2089.	2.5	17
286	The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 72, e901-e913.	2.9	35
287	Double trouble: combined cardiovascular effects of particulate matter exposure and coronavirus disease 2019. <i>Cardiovascular Research</i> , 2021, 117, 85-95.	1.8	15
288	Cardiac Involvement of COVID-19: A Comprehensive Review. <i>American Journal of the Medical Sciences</i> , 2021, 361, 14-22.	0.4	104
289	The role of inflammation in hypertension: novel concepts. <i>Current Opinion in Physiology</i> , 2021, 19, 92-98.	0.9	57
290	Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1-12.	5.7	93
291	Using genetics to understand the role of antihypertensive drugs modulating angiotensin-converting enzyme in immune function and inflammation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1839-1846.	1.1	5
292	Visceral fat is associated to the severity of COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154440.	1.5	100
293	A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. , 2021, 221, 107750.		34
294	The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities. <i>Infection, Genetics and Evolution</i> , 2021, 87, 104647.	1.0	60
295	Recent efforts in drug discovery on vascular inflammation and consequent atherosclerosis. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 411-427.	2.5	7
296	Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. <i>Archives of Disease in Childhood</i> , 2021, 106, 429-439.	1.0	374
297	Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 476-485.	2.9	46
298	Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. <i>Journal of Clinical Hypertension</i> , 2021, 23, 21-27.	1.0	31
299	Insights into heart failure hospitalizations, management, and services during and beyond COVID-19. <i>ESC Heart Failure</i> , 2021, 8, 175-182.	1.4	22
300	Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L301-L330.	1.3	26
301	Comparison of clinical characteristics of patients with pandemic SARS-CoV-2-related and community-acquired pneumonias in Hungary - a pilot historical case-control study. <i>GeroScience</i> , 2021, 43, 53-64.	2.1	4

#	ARTICLE	IF	CITATIONS
302	Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications. <i>Acta Cardiologica</i> , 2021, 76, 109-124.	0.3	42
303	Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2475-2492.	1.1	27
304	ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19. <i>Journal of Internal Medicine</i> , 2021, 289, 688-699.	2.7	26
305	Insights into disparities observed with COVID-19. <i>Journal of Internal Medicine</i> , 2021, 289, 463-473.	2.7	92
306	Zoonotic coronavirus epidemics. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 321-337.	0.5	8
307	How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity. <i>European Journal of Internal Medicine</i> , 2021, 83, 1-5.	1.0	35
308	A data-driven approach to identify risk profiles and protective drugs in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	32
309	The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 190-195.	0.3	22
310	Outcome of patients hospitalized for Covid-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: Results of the ACECoV study. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 192-193.	1.0	2
312	SARS-CoV-2: cÃ³mo es, cÃ³mo actÃ³a y cÃ³mo se expresa en la imagen. <i>Radiologia</i> , 2021, 63, 115-126.	0.3	7
313	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824650 Patients With Hypertension From a US Integrated Healthcare System. <i>Journal of the American Heart Association</i> , 2021, 10, e019669.	1.6	26
314	Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. <i>The Lancet Digital Health</i> , 2021, 3, e98-e114.	5.9	94
315	Conflicts over calcium and the treatment of COVID-19. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 149-156.	1.1	49
316	SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis. <i>Thorax</i> , 2021, 76, 370-379.	2.7	15
317	The role of renin-angiotensin system activated phagocytes in the SARS-CoV-2 coronavirus infection. <i>Journal of Vascular Surgery</i> , 2021, 73, 1889-1897.	0.6	4
318	The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2021, 50, 75-86.	0.9	10
319	Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI). <i>American Journal of the Medical Sciences</i> , 2021, 361, 287-296.	0.4	20
320	Mortality associated with cardiovascular disease in patients with COVID-19. <i>REC: CardioClinics</i> , 2021, 56, 30-38.	0.1	13

#	ARTICLE	IF	CITATIONS
321	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 87-94.	0.4	259
322	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. <i>Nature Biotechnology</i> , 2021, 39, 705-716.	9.4	129
323	Translating bioactive peptides for COVID-19 therapy. <i>European Journal of Pharmacology</i> , 2021, 890, 173661.	1.7	15
324	The pivotal role of the angiotensin-II- $\text{NF-}\kappa\text{B}$ axis in the development of COVID-19 pathophysiology. <i>Hypertension Research</i> , 2021, 44, 126-128.	1.5	18
325	Cardiology and COVID-19: do we have sufficient information?. <i>Future Cardiology</i> , 2021, 17, 705-711.	0.5	2
326	Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19. <i>Angiology</i> , 2021, 72, 122-130.	0.8	20
327	Beyond dexamethasone, emerging immunothrombotic therapies for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 845-857.	1.1	6
328	Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review. <i>CJC Open</i> , 2021, 3, 28-40.	0.7	7
329	Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. <i>Canadian Journal of Diabetes</i> , 2021, 45, 162-166.e1.	0.4	19
330	Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. <i>Immunology and Cell Biology</i> , 2021, 99, 192-205.	1.0	5
331	History and Recent Advances in Coronavirus Discovery. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 3-24.	0.1	3
332	The renin-angiotensin system in pediatric kidney disease: from pathophysiology to the novel therapeutic approach. <i>Japanese Journal of Pediatric Nephrology</i> , 2021, 34, 7-12.	0.0	0
333	The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. <i>Heart Failure Reviews</i> , 2021, 26, 961-971.	1.7	10
334	Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 245-249.	0.9	4
335	SARS-CoV-2 host cell interactions and pathways: understanding its physiology, pathology, and targeted drug therapy. , 2021, , 185-210.		0
336	Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. <i>World Journal of Clinical Cases</i> , 2021, 9, 47-60.	0.3	3
337	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. <i>European Heart Journal</i> , 2021, 42, 657-670.	1.0	25
338	Active vitamin D supplementation and COVID-19 infections: review. <i>Irish Journal of Medical Science</i> , 2021, 190, 1271-1274.	0.8	11

#	ARTICLE	IF	CITATIONS
339	RAAS-Blockade in COVID-19: The Ace of Spades?. Indian Journal of Nephrology, 2021, 31, 423.	0.2	0
340	A Potential Role of the Renin-Angiotensin-System for Disturbances of Respiratory Chemosensitivity in Acute Respiratory Distress Syndrome and Severe Acute Respiratory Syndrome. Frontiers in Physiology, 2020, 11, 588248.	1.3	6
342	COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice. Current Hypertension Reviews, 2021, 17, .	0.5	2
343	COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 905-919.	1.3	445
344	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 254.	3.8	299
345	Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy. Drug Development Research, 2021, 82, 469-473.	1.4	24
346	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Frontiers in Physiology, 2021, 12, 593223.	1.3	113
347	Applications of Artificial Intelligence (AI) for cardiology during COVID-19 pandemic. Sustainable Operations and Computers, 2021, 2, 71-78.	6.3	25
348	Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19). Southern Medical Journal, 2021, 114, 51-56.	0.3	14
349	COVID-19 in Patients with Hypertension. Advances in Experimental Medicine and Biology, 2021, 1318, 243-261.	0.8	3
350	Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19. Advances in Experimental Medicine and Biology, 2021, 1327, 205-214.	0.8	13
351	COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. Journal of Human Hypertension, 2021, 35, 304-307.	1.0	60
352	The association between blood pressure levels and mortality in critically ill patients with COVID-19 in Wuhan, China: a case-series report. Hypertension Research, 2021, 44, 368-370.	1.5	11
353	Mortality and other outcomes of patients with coronavirus disease pneumonia admitted to the emergency department: A prospective observational Brazilian study. PLoS ONE, 2021, 16, e0244532.	1.1	18
354	Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 5-11.	1.0	21
355	Antihypertensives and their relation to mortality by SARS-CoV-2 infection. Journal of Medical Virology, 2021, 93, 2467-2475.	2.5	4
356	Epidemiological and clinical characteristics of 5,628 patients with coronavirus disease 2019 in South Korea: A nationwide multicenter study. Allergy Asthma & Respiratory Disease, 2021, 9, 136.	0.3	2
357	Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review. Clinics, 2021, 76, e2342.	0.6	8

#	ARTICLE	IF	CITATIONS
358	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2â€”care pathways, treatment, and follow-up. <i>European Heart Journal</i> , 2022, 43, 1059-1103.	1.0	111
359	Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. <i>Clinical Research in Cardiology</i> , 2021, 110, 1041-1050.	1.5	49
360	Ecological Analysis of the Influence of ACEIs and ARBs on the COVID-19 Prevalence and Death from COVID-19. <i>Health</i> , 2021, 13, 619-628.	0.1	1
361	Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. <i>Clinical Science</i> , 2021, 135, 1-17.	1.8	17
362	Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis. <i>Thorax</i> , 2021, 76, 479-486.	2.7	16
363	No association between use of angiotensinâ€”converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVIDâ€”19 in the COvid ME dica Tion (COMET) study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3301-3309.	1.1	6
364	An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 630209.	1.2	16
365	Androgens, the kidney, and COVID-19: an opportunity for translational research. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F243-F248.	1.3	5
366	The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. <i>Acta Diabetologica</i> , 2021, 58, 831-843.	1.2	46
367	To Curb the Progression of Fatal COVID-19 Courseâ€”Dream or Reality. <i>Current Hypertension Reports</i> , 2021, 23, 12.	1.5	3
368	Reninâ€”angiotensin system blockade in the COVID-19 pandemic. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, i48-i59.	1.4	17
369	Reninâ€”angiotensin system inhibitors and COVID-19: overwhelming evidence against an association. <i>The Lancet Digital Health</i> , 2021, 3, e70-e71.	5.9	2
370	Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities. <i>Current Opinion in Anaesthesiology</i> , 2021, 34, 187-198.	0.9	1
371	Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic. <i>Frontiers in Physiology</i> , 2021, 12, 624052.	1.3	12
373	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. <i>Frontiers in Medicine</i> , 2021, 8, 604087.	1.2	1
374	Efficacy of Serum Angiotensin II Levels in Prognosis of Patients With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2021, 49, e613-e623.	0.4	23
376	Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 483-488.	1.3	13
377	Prospective meta-analysis protocol on randomised trials of reninâ€”angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension. <i>BMJ Open</i> , 2021, 11, e043625.	0.8	11

#	ARTICLE	IF	CITATIONS
378	The swedish covid-19 intensive care cohort: Risk factors of ICU admission and ICU mortality. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 525-533.	0.7	59
379	Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 129-139.	1.0	41
380	Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 1325.	5.8	133
381	Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults. <i>Annals of Internal Medicine</i> , 2021, 174, W25-W29.	2.0	9
383	Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. <i>Journal of Hypertension</i> , 2021, 39, 784-794.	0.3	34
385	Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms. <i>Journal of Vascular Surgery</i> , 2021, 74, 1740-1751.	0.6	16
386	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 772-810.	1.2	612
387	Coronavirus disease 2019 and cardiovascular complications: focused clinical review. <i>Journal of Hypertension</i> , 2021, 39, 1282-1292.	0.3	62
388	Low birth weight as a potential risk factor for severe COVID-19 in adults. <i>Scientific Reports</i> , 2021, 11, 2909.	1.6	10
389	Neurological symptoms of COVID-19. <i>Pharmacotherapy in Psychiatry and Neurology</i> , 2021, 36, 285-296.	0.1	0
390	Hypertension artérielle et COVID-19. <i>La Presse Médicale Formation</i> , 2021, 2, 25-32.	0.1	2
391	Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis. <i>Egyptian Heart Journal</i> , 2021, 73, 13.	0.4	5
392	Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. <i>American Journal of Hematology</i> , 2021, 96, 471-479.	2.0	129
393	Influence of renin-angiotensin-aldosterone system inhibitors on plasma levels of angiotensin-converting enzyme 2. <i>ESC Heart Failure</i> , 2021, 8, 1717-1721.	1.4	8
394	Could Renin-Angiotensin System Inhibitors Be Protective From Severe COVID-19?. <i>Hypertension</i> , 2021, 77, 843-845.	1.3	1
395	SARS-CoV-2: what it is, how it acts, and how it manifests in imaging studies. <i>Radiologia</i> , 2021, 63, 115-126.	0.3	3
396	Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts. <i>PLoS ONE</i> , 2021, 16, e0247548.	1.1	8
397	An Overview of Drugs Used in COVID-19: A Pharmacotherapeutic Approach. <i>International Journal of Health Sciences and Pharmacy</i> , 0, , 34-54.	0.0	0

#	ARTICLE	IF	CITATIONS
398	Problem issues of the pathogenesis of inflammatory reaction and the course of coronavirus infection. <i>Tuberculosis Lung Diseases HIV Infection</i> , 2021, , 76-86.	0.3	0
400	Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. <i>Health Care Management Science</i> , 2021, 24, 339-355.	1.5	8
401	COVID-19 and its impact on the cardiovascular system. <i>Open Heart</i> , 2021, 8, e001472.	0.9	27
402	Clinical manifestations and outcomes of coronavirus diseaseâ€19 in heart transplant recipients: a multicentre case series with a systematic review and metaâ€analysis. <i>Transplant International</i> , 2021, 34, 721-731.	0.8	9
403	COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1083-1092.	2.0	13
404	Nicotinic cholinergic system and COVID-19: In silico identification of interactions between Î±7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins. <i>Food and Chemical Toxicology</i> , 2021, 149, 112009.	1.8	46
405	Outcomes of COVIDâ€19â€positive acute coronary syndrome patients: A multisource electronic healthcare records study from England. <i>Journal of Internal Medicine</i> , 2021, 290, 88-100.	2.7	43
406	Pre-existing conditions in Hispanics/Latinxs that are COVID-19 risk factors. <i>IScience</i> , 2021, 24, 102188.	1.9	13
407	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. <i>International Journal of Infectious Diseases</i> , 2021, 104, 7-14.	1.5	13
408	Antivirals with common targets against highly pathogenic viruses. <i>Cell</i> , 2021, 184, 1604-1620.	13.5	78
409	Antihypertensive Drugs and COVID-19 Risk. <i>Hypertension</i> , 2021, 77, 833-842.	1.3	94
410	Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis. <i>Scientific Reports</i> , 2021, 11, 5012.	1.6	18
411	Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection. <i>Journal of Traditional and Complementary Medicine</i> , 2021, 11, 144-157.	1.5	49
412	Risk of SARS-CoV-2 infection and COVID-19 prognosis with the use of reninâ€angiotensinâ€aldosterone system (RAAS) inhibitors: a systematic review. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 73.	1.1	8
414	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 255-262.	1.0	1
415	SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 4945.	1.6	19
416	Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e213594.	2.8	92
417	The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review. <i>Current Hypertension Reports</i> , 2021, 23, 17.	1.5	6

#	ARTICLE	IF	CITATIONS
419	Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S114-S122.	0.7	11
420	Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies. <i>Hypertension Research</i> , 2021, 44, 955-968.	1.5	15
421	Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 275-284.	5.2	198
422	Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome. <i>Pharmaceutics</i> , 2021, 13, 431.	2.0	2
423	Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease. <i>Frontiers in Medicine</i> , 2021, 8, 600385.	1.2	13
426	Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S123-S131.	0.7	12
427	Renin-angiotensin system inhibitors in hospitalised patients with COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, 221-222.	5.2	7
428	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
429	Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 620990.	1.2	26
430	Development and multicenter validation of a CT-based radiomics signature for predicting severe COVID-19 pneumonia. <i>European Radiology</i> , 2021, 31, 7901-7912.	2.3	18
431	Treatment of hypertension during the COVID-19 pandemic: questions about the blockade of the renin-angiotensin-aldosterone system. <i>Meditinskiy Sovet</i> , 2021, , 59-67.	0.1	0
432	The effect of renin-angiotensin-aldosterone blockers on SARS-CoV-2 infection in adults: a systematic review of studies and meta-analyses. <i>Meditinskiy Sovet</i> , 2021, , 26-33.	0.1	0
433	Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease. <i>Journal of Hypertension</i> , 2021, 39, 1717-1724.	0.3	22
434	Hypertension, a Moving Target in COVID-19. <i>Circulation Research</i> , 2021, 128, 1062-1079.	2.0	61
436	Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease. <i>Open Heart</i> , 2021, 8, e001526.	0.9	22
437	Drugs acting on the renin-angiotensin system and SARS-CoV-2. <i>Drug Discovery Today</i> , 2021, 26, 870-874.	3.2	33
438	Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem. <i>Advances in Therapy</i> , 2021, 38, 2709-2716.	1.3	2
439	Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. <i>Viruses</i> , 2021, 13, 700.	1.5	249

#	ARTICLE	IF	CITATIONS
440	Does taking an angiotensin inhibitor increase the risk for COVID-19? â€“ a systematic review and meta-analysis. <i>Aging</i> , 2021, 13, 10853-10865.	1.4	7
441	Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-10.	0.6	18
442	The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 667254.	1.6	39
444	Chronic use of reninâ€“angiotensinâ€“aldosterone system blockers and mortality in COVIDâ€“19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.0	4
445	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. <i>Cardiologia Croatica</i> , 2021, 16, 140-156.	0.0	0
446	Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129. <i>Cardiovascular Research</i> , 2021, 117, 1823-1840.	1.8	17
447	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. <i>Science Progress</i> , 2021, 104, 003685042110169.	1.0	15
448	The fight against COVID-19: Striking a balance in the reninâ€“angiotensin system. <i>Drug Discovery Today</i> , 2021, 26, 2214-2220.	3.2	11
449	Physical Activity and the Risk of COVID-19 Infection and Mortality: A Nationwide Population-Based Case-Control Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1539.	1.0	33
450	RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. <i>Contemporary Clinical Trials</i> , 2021, 103, 106330.	0.8	9
451	The Interplay Between the Immune System, the Reninâ€“Angiotensinâ€“Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVIDâ€“19: A Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 987-1000.	1.0	11
452	Proteinuria changes in kidney disease patients with clinical remission during the COVID-19 pandemic. <i>PLoS ONE</i> , 2021, 16, e0250581.	1.1	1
453	Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19. <i>European Journal of Endocrinology</i> , 2021, 184, 543-552.	1.9	29
454	Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburgâ€“a report from the AGMT COVID-19 Registry. <i>GeroScience</i> , 2021, 43, 1877-1897.	2.1	3
455	Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab170.	0.4	2
456	Associations Between the Use of Reninâ€“Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 609857.	1.1	11
457	Review of Pharmacotherapy Tried for Management of the Coronavirus Disease-19. <i>Eurasian Journal of Medicine</i> , 2021, 53, 137-143.	0.2	5
458	Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study). <i>American Journal of Cardiology</i> , 2021, 147, 58-60.	0.7	4

#	ARTICLE	IF	CITATIONS
460	Predictors of fatal outcomes among hospitalized COVID-19 patients with pre-existing hypertension in China. <i>Clinical Respiratory Journal</i> , 2021, 15, 915-924.	0.6	8
461	Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis. <i>Medicina Clínica</i> , 2022, 158, 315-323.	0.3	10
462	Learning to learn by yourself: Unsupervised meta-learning with self-knowledge distillation for COVID-19 diagnosis from pneumonia cases. <i>International Journal of Intelligent Systems</i> , 2021, 36, 4033-4064.	3.3	10
463	Therapeutic approaches targeting renin-angiotensin system in sepsis and its complications. <i>Pharmacological Research</i> , 2021, 167, 105409.	3.1	18
464	The role of the angiotensins in the pathogenesis of inflammatory joint disease. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 635-639.	0.2	0
465	Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1323-1330.	1.8	26
466	Antihypertensive medications and COVID-19 diagnosis and mortality: Population-based case-control analysis in the United Kingdom. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4598-4607.	1.1	18
467	Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 617-628.	0.7	3
468	Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4421-4431.	1.1	39
469	A preliminary metabolites identification of a novel compound with β^2 -adrenolytic activity. <i>Pharmacological Reports</i> , 2021, 73, 1373-1389.	1.5	1
470	Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 577398.	1.1	3
471	Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 430-438.	1.8	4
472	Insights into SARS-CoV-2 Persistence and Its Relevance. <i>Viruses</i> , 2021, 13, 1025.	1.5	37
473	Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies. <i>Pathogens</i> , 2021, 10, 582.	1.2	17
474	Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study. <i>BMC Medicine</i> , 2021, 19, 118.	2.3	14
475	Smoking and risk of COVID-19 hospitalization. <i>Respiratory Medicine</i> , 2021, 182, 106414.	1.3	33
476	A Comparative Review of Methods For Estimation of Some Antihypertensive Drugs in Pharmaceutical Production. <i>Egyptian Journal of Chemistry</i> , 2021, .	0.1	0
477	COVID-19 Causing Hypotension in Frail Geriatric Hypertensive Patients?. <i>Medicina (Lithuania)</i> , 2021, 57, 633.	0.8	6

#	ARTICLE	IF	CITATIONS
478	Safety and Efficacy of Renin-angiotensin-aldosterone System Inhibitors in COVID-19 Population. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 405-416.	1.0	7
479	Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis. Scientific Reports, 2021, 11, 13588.	1.6	8
480	The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1589-1593.	1.4	8
481	Coronavirus Disease 2019 and Cardiometabolic Disease. Cardiology in Review, 2022, 30, 123-128.	0.6	9
482	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. CJC Open, 2021, 3, 1257-1272.	0.7	18
483	COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 705-715.	8.2	26
484	COVID-19 Pandemic and Virtual Clinics for Diabetes Care. Diabetes Technology and Therapeutics, 2021, 23, S-3-S-15.	2.4	6
485	Hypertension, Obesity, and COVID-19: a Collision of Pandemics. Current Hypertension Reports, 2021, 23, 36.	1.5	14
486	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. Journal of Clinical Medicine, 2021, 10, 2642.	1.0	9
487	Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1061-1072.	2.2	7
488	Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes. BMC Infectious Diseases, 2021, 21, 527.	1.3	9
489	Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients. PLoS ONE, 2021, 16, e0252799.	1.1	81
490	COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. Frontiers in Endocrinology, 2021, 12, 649525.	1.5	124
491	Does Baseline Diuretics Use Affect Prognosis in Patients With COVID-19?. Cureus, 2021, 13, e15573.	0.2	4
492	Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. Biomedicine and Pharmacotherapy, 2021, 138, 111469.	2.5	3
493	Correlation between Coronavirus Disease 2019 and Heart Failure: A Review. Journal of Regenerative Biology and Medicine, 0, , .	0.0	0
494	Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension. Frontiers of Medicine, 2022, 16, 102-110.	1.5	10
495	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 239-254.	0.2	40

#	ARTICLE	IF	CITATIONS
497	A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. <i>EClinicalMedicine</i> , 2021, 37, 100957.	3.2	56
498	Pharmacological management of COVID-19 in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107927.	1.2	14
499	IL-10 and IL-12 (P70) Levels Predict the Risk of Covid-19 Progression in Hypertensive Patients: Insights From the BRACE-CORONA Trial. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 702507.	1.1	23
500	To Adjust or Not to Adjust: The Role of Different Covariates in Cardiovascular Observational Studies. <i>American Heart Journal</i> , 2021, 237, 62-67.	1.2	44
501	Severe COVID-19 has a distinct phenotype from bacterial sepsis: a retrospective cohort study in deceased patients. <i>Annals of Translational Medicine</i> , 2021, 9, 1054-1054.	0.7	4
502	Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8255.	1.8	30
503	Risk of Coronavirus Disease 2019 Occurrence, Severe Presentation, and Mortality in Patients with Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 678-684.	1.3	13
504	Development of flexible electrochemical impedance spectroscopy-based biosensing platform for rapid screening of SARS-CoV-2 inhibitors. <i>Biosensors and Bioelectronics</i> , 2021, 183, 113213.	5.3	44
505	Arterial hypertension. <i>Lancet, The</i> , 2021, 398, 249-261.	6.3	100
506	Predictors of COVID-19 in an outpatient fever clinic. <i>PLoS ONE</i> , 2021, 16, e0254990.	1.1	6
507	Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings. <i>European Journal of Heart Failure</i> , 2021, 23, 1891-1902.	2.9	21
508	Bacille Calmette-Guérin: An Ophthalmic perspective. <i>Survey of Ophthalmology</i> , 2021, , .	1.7	2
509	Role of Hypertension on the Severity of COVID-19: A Review. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, e648-e655.	0.8	64
510	Lock, Stock and Barrel: Role of Renin-Angiotensin-Aldosterone System in Coronavirus Disease 2019. <i>Cells</i> , 2021, 10, 1752.	1.8	12
512	Dihydropyridine Calcium Channel Blockers and the Risk of Severe COVID-19. <i>Chest</i> , 2021, 160, 89-93.	0.4	17
513	Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for) Tj ETQq1 1 0.784314. https://doi.org/10.1093/ckp/ckaa107	1.0	10
514	Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19. <i>Journal of the American Heart Association</i> , 2021, 10, e018086.	1.6	45
515	NSAIDs and COVID-19: A Systematic Review and Meta-analysis. <i>Drug Safety</i> , 2021, 44, 929-938.	1.4	53

#	ARTICLE	IF	CITATIONS
516	Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?. <i>Clinical and Experimental Hypertension</i> , 2021, , 1-10.	0.5	5
517	Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19. <i>Journal of the American Heart Association</i> , 2021, 10, e021154.	1.6	10
518	Pronóstico de los pacientes hospitalizados por Covid-19 que utilizaban inhibidores de la enzima convertidora de angiotensina o antagonistas del receptor de angiotensina II. <i>Repertorio De Medicina Y Cirugia</i> , 0, , .	0.0	0
519	The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review. <i>Microorganisms</i> , 2021, 9, 1692.	1.6	22
520	Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 863-872.	5.2	75
521	Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease. <i>Scientific Reports</i> , 2021, 11, 16843.	1.6	7
522	Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?. <i>Advances in Biological Regulation</i> , 2021, 81, 100820.	1.4	15
523	Is diabetes mellitus a wrongdoer to COVID-19 severity?. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108936.	1.1	9
524	Pre-Existing Diabetes and COVID-Associated Hyperglycaemia in Patients with COVID-19 Pneumonia. <i>Biology</i> , 2021, 10, 754.	1.3	5
525	Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology. <i>CJC Open</i> , 2021, 3, 1060-1074.	0.7	14
526	Protocol for the Controlled evaluation of Angiotensin Receptor blockers for COVID-19 respiratory disease (CLARITY): a randomised controlled trial. <i>Trials</i> , 2021, 22, 573.	0.7	7
527	Paradoxical effects of cigarette smoke and COPD on SARS-CoV-2 infection and disease. <i>BMC Pulmonary Medicine</i> , 2021, 21, 275.	0.8	9
528	Cardiovascular ACE2 receptor expression in patients undergoing heart transplantation. <i>ESC Heart Failure</i> , 2021, 8, 4119-4129.	1.4	7
529	Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada. <i>JAMA Network Open</i> , 2021, 4, e2118441.	2.8	67
530	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. <i>Nutrients</i> , 2021, 13, 2830.	1.7	27
531	Fighting the pandemic with collaboration at heart: Report from cardiologists in a COVID-19-dedicated Portuguese intensive care unit. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 923-928.	0.2	5
532	Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults. <i>Drugs and Aging</i> , 2021, 38, 921-930.	1.3	5
533	The effects of COVID-19 pandemic on patients with lower extremity peripheral arterial disease: A near miss disaster. <i>Annals of Vascular Surgery</i> , 2021, 77, 71-78.	0.4	11

#	ARTICLE	IF	CITATIONS
534	Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2455-2474.	0.9	2
535	Updates on Renin-Â“Angiotensin System Blockers in Hypertensive Patients With COVID-19. <i>American Journal of Hypertension</i> , 2021, , .	1.0	4
536	Metabolic syndrome and the risk of COVID-19 infection: A nationwide population-based case-control study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2596-2604.	1.1	14
537	ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes. <i>Acta Physiologica</i> , 2021, 233, e13733.	1.8	12
538	Cardiovascular system and coronavirus disease-2019 (COVID-19): mutual injuries and unexpected outcomes. <i>Egyptian Heart Journal</i> , 2021, 73, 77.	0.4	4
539	COVID-19 and the cardiovascular system: insights into effects and treatments. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 1119-1127.	0.7	6
540	Use of Calcium Channel Blockers and the Risk of All-cause Mortality and Severe Illness in Patients With COVID-19: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 199-205.	0.8	4
541	Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis. <i>International Immunopharmacology</i> , 2021, 98, 107806.	1.7	35
543	Clinical aspects of SARS-CoV-2 infection and vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 287-291.	2.6	9
544	Final results of BIRCOV trial (ARB, ACEI, DRi in COVID-19). <i>PoÅki</i> , 2021, 10, 143-149.	0.1	2
545	Complication and Sequelae of COVID-19: What Should We Pay Attention to in the Post-Epidemic Era. <i>Frontiers in Immunology</i> , 2021, 12, 711741.	2.2	18
546	Hypertensive urgencies during the first wave of COVID-19 pandemic in a tertiary hospital setting: A shaped alarming curve.. <i>Archives of Medical Science</i> , 2021, , .	0.4	4
547	Association of renin-Â“angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	6
548	Risk factors for hospitalization among persons with COVID-19-Colorado. <i>PLoS ONE</i> , 2021, 16, e0256917.	1.1	32
549	Current Data on the Directions of Therapy of Essential Hypertension in Patients with Metabolic Syndrome and COVID-19 and Possibilities for Prevention of Long-Term Complications. <i>Ukrainian Journal of Medicine</i> , 2021, 6, 6-14.	0.0	0
550	Arterial hypertension - Clinical trials update 2021. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 21-31.	1.1	42
551	The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with Type 2 diabetes: A systematic review. <i>Primary Care Diabetes</i> , 2021, 15, 899-909.	0.9	11
552	Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality. <i>Systematic Reviews</i> , 2021, 10, 243.	2.5	7

#	ARTICLE	IF	CITATIONS
553	Prevalence and characteristics of myocardial injury during COVID-19 pandemic: A new role for high-sensitive troponin. <i>International Journal of Cardiology</i> , 2021, 338, 278-285.	0.8	18
554	Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells. <i>Stem Cell Reports</i> , 2021, 16, 2459-2472.	2.3	11
555	COVID-19 and chronic kidney disease: a comprehensive review. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 383-399.	0.4	32
557	The Crosstalk between SARS-CoV-2 Infection and the RAA System in Essential Hypertension—Analyses Using Systems Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10518.	1.8	3
558	Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms. <i>Journal of Neuroimmunology</i> , 2021, 358, 577658.	1.1	52
559	Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium. <i>BMJ Open</i> , 2021, 11, e053393.	0.8	5
560	Role of Cardiac Biomarkers in COVID-19: What Recent Investigations Tell Us?. <i>Current Problems in Cardiology</i> , 2021, 46, 100842.	1.1	16
562	Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension. <i>Journal of General Internal Medicine</i> , 2021, 36, 3802-3809.	1.3	2
563	Renin—angiotensin—aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system. <i>American Heart Journal</i> , 2021, 240, 46-57.	1.2	4
564	COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment — A narrative review. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2021, 35, 351-368.	1.7	57
565	In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
566	Drugs for the Treatment of COVID-19. , 2021, , 193-204.		0
567	Serum Renin Levels Increase With Age in Boys Resulting in Higher Renin Levels in Young Men Compared to Young Women, and Soluble Angiotensin-Converting Enzyme 2 Correlates With Renin and Body Mass Index. <i>Frontiers in Physiology</i> , 2020, 11, 622179.	1.3	6
568	COVID-19 and Vulnerable Populations in Sub-Saharan Africa. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1321, 147-162.	0.8	2
569	Renin—angiotensin—aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110113.	1.0	10
570	COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 452-459.	0.9	2
571	The influence of pre-existing hypertension on coronavirus disease 2019 patients. <i>Epidemiology and Infection</i> , 2021, 149, e4.	1.0	14
572	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. <i>European Heart Journal</i> , 2022, 43, 1033-1058.	1.0	80

#	ARTICLE	IF	CITATIONS
573	Association between COVID-19 and angiotensin-converting enzyme inhibitors with the spotlight on zinc: an opinion. <i>Annals of Medicine</i> , 2021, 53, 1673-1675.	1.5	1
574	A case report of super responder of critical COVID-19 pneumonia. <i>Journal of Medical Investigation</i> , 2021, 68, 192-195.	0.2	1
575	AtualizaÃ§Ã£o de TÃ³picos Emergentes da Diretriz Brasileira de InsuficiÃªncia CardÃaca â€“ 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 1174-1212.	0.3	13
576	Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. <i>Biomolecules</i> , 2021, 11, 196.	1.8	4
577	A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19. <i>Open Journal of Biophysics</i> , 2021, 11, 1-67.	0.7	1
578	COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects. <i>Frontiers in Medicine</i> , 2020, 7, 627278.	1.2	24
579	Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 37-50.	1.1	17
580	SARS-CoV-2-induced Overexpression of miR-4485 Suppresses Osteogenic Differentiation and Impairs Fracture Healing. <i>International Journal of Biological Sciences</i> , 2021, 17, 1277-1288.	2.6	29
581	Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. <i>Cerebrovascular Diseases</i> , 2021, 50, 245-261.	0.8	32
582	First results of the â€œLean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)â€•. <i>Infection</i> , 2021, 49, 63-73.	2.3	62
583	Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports. <i>Diabetes and Metabolism</i> , 2020, 46, 265-271.	1.4	119
584	SARS-CoV-2 and diabetes: New challenges for the disease. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108228.	1.1	48
585	Angiotensin converting enzyme-2 as therapeutic target in COVID-19. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 637-639.	1.8	50
586	The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the â€œAriadne's threadâ€•for the â€œlabyrinthâ€•of COVID-19. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 31-33.	0.4	6
587	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. <i>Vascular Pharmacology</i> , 2020, 135, 106805.	1.0	39
588	A historical perspective on ACE2 in the COVID-19 era. <i>Journal of Human Hypertension</i> , 2021, 35, 935-939.	1.0	41
589	RAAS inhibitors do not increase the risk of COVID-19. <i>Nature Reviews Cardiology</i> , 2020, 17, 383-383.	6.1	16
590	Proliferation of Papers and Preprints During the Coronavirus Disease 2019 Pandemic: Progress or Problems With Peer Review?. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 418-426.	0.6	44

#	ARTICLE	IF	CITATIONS
591	Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. <i>Blood Pressure</i> , 2021, 30, 1-3.	0.7	16
592	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1009-1027.	2.0	23
593	Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2121-2128.	2.9	93
594	Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2129-2131.	2.9	5
595	Coronavirus disease 2019 in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 297-306.	1.4	59
596	Neutrophil:lymphocyte ratio predicts short-term outcome of COVID-19 in haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 124-131.	1.4	19
597	Fabry disease and COVID-19: international expert recommendations for management based on real-world experience. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 913-925.	1.4	11
598	Adverse effects of sympathetic activation should not be neglected during the coronavirus disease 2019 pandemic. <i>Chinese Medical Journal</i> , 2021, 134, 413-414.	0.9	4
599	Inflammatory Cardiomyopathy: Case-based Review on Clinical Presentation, Diagnosis, and Management. <i>Cardiology in Review</i> , 2021, 29, 230-237.	0.6	2
600	Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients. <i>Journal of Hypertension</i> , 2020, 38, 2537-2541.	0.3	20
601	Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment. <i>Journal of Hypertension</i> , 2021, 39, 367-375.	0.3	17
602	Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding. <i>Journal of Hypertension</i> , 2021, 39, 795-805.	0.3	41
603	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.5	5
624	Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital. <i>Journal of Clinical Hypertension</i> , 2021, 23, 218-231.	1.0	50
625	COVID-19 and Oxidative Stress. <i>Biochemistry (Moscow)</i> , 2020, 85, 1543-1553.	0.7	168
626	COVID-19 and the heart: what we have learnt so far. <i>Postgraduate Medical Journal</i> , 2021, 97, 655-666.	0.9	10
627	A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. <i>Medical Science Monitor</i> , 2020, 26, e926651.	0.5	16
628	High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. <i>PLoS ONE</i> , 2020, 15, e0244131.	1.1	46

#	ARTICLE	IF	CITATIONS
629	Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia. PLoS ONE, 2020, 15, e0244349.	1.1	7
630	Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study. PLoS ONE, 2020, 15, e0244708.	1.1	7
631	Chronic ACE Inhibitor use is Associated with Decreased Odds of Severe Disease in Patients with COVID-19. Anatolian Journal of Cardiology, 2020, 24, 21-29.	0.5	36
632	Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. Journal of Endocrinology, 2020, 247, R45-R62.	1.2	43
633	The Coronavirus Disease 2019 Outbreak Highlights the Importance of Sex-sensitive Medicine. European Cardiology Review, 2020, 15, e62.	0.7	3
634	Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2580.	0.4	6
635	Commonalities Between COVID-19 and Radiation Injury. Radiation Research, 2020, 195, 1-24.	0.7	23
636	Editorial: COVID-19 and the quality use of medicines: evidence, risks and fads. Australian Prescriber, 2020, 43, 78-80.	0.5	5
637	Cardiovascular Considerations in Coronavirus Disease 2019 with a Special Focus on Arrhythmia. Journal of Innovations in Cardiac Rhythm Management, 2020, 11, 4191-4198.	0.2	4
639	Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?. Minerva Cardioangiologica, 2020, 68, 339-346.	1.2	2
640	COVID-19 and comorbid chronic diseases. Infusion & Chemotherapy, 2020, , 5-10.	0.0	4
641	The Physiological Mechanisms of the Sex-Based Difference in Outcomes of COVID19 Infection. Frontiers in Physiology, 2021, 12, 627260.	1.3	32
642	Risk factors and interventions associated with mortality or survival in adult COVID-19 patients admitted to critical care: a systematic review and meta-analysis. Southern African Journal of Anaesthesia and Analgesia, 2020, 26, 116-127.	0.1	9
643	C�ncer e Doen�as Cardiovasculares na Pandemia de COVID-19. Arquivos Brasileiros De Cardiologia, 2020, 115, 547-557.	0.3	5
644	COVID-19 and the kidney. Cleveland Clinic Journal of Medicine, 2020, 87, 619-631.	0.6	52
645	Renin-angiotensin system inhibitors in COVID-19. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	7
646	Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective. Diabetes and Metabolism Journal, 2020, 44, 372.	1.8	14
647	Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study. Epidemiology and Health, 2021, 43, e2021004.	0.8	10

#	ARTICLE	IF	CITATIONS
648	Coronavirus Disease 2019 (COVID-19): The Singapore Experience. A Review of the First Eight Months. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 764-778.	0.2	27
649	Hypertension and Electrolyte Disorders in Patients with COVID-19. <i>Electrolyte and Blood Pressure</i> , 2020, 18, 23.	0.6	13
650	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. <i>Global Heart</i> , 2020, 15, 44.	0.9	11
651	COVID-19 and acute kidney injury. <i>Tuberkuloz Ve Toraks</i> , 2020, 68, 407-418.	0.2	30
652	Proper Management of People with Obesity during the COVID-19 Pandemic. <i>Journal of Obesity and Metabolic Syndrome</i> , 2020, 29, 84-98.	1.5	34
653	An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100063.	1.7	7
654	MATHEMATICAL MODEL FOR THE INVESTIGATION OF HYPOXIC STATES IN THE HEART MUSCLE AT VIRAL DAMAGE. <i>Biotechnologia Acta</i> , 2021, 14, 38-52.	0.3	0
655	Importance of diabetes management during the COVID-19 pandemic. <i>Postgraduate Medicine</i> , 2021, 133, 912-919.	0.9	8
656	On the problem of the relationship between arterial hypertension and coronavirus disease (COVID-19): literature review. <i>Hypertension</i> , 2021, 14, 40-45.	0.2	0
657	Evaluation of early antibiotic use in patients with non-severe COVID-19 without bacterial infection. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106462.	1.1	13
658	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
659	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
660	Comparing automated vs. manual data collection for COVID-specific medications from electronic health records. <i>International Journal of Medical Informatics</i> , 2022, 157, 104622.	1.6	11
661	Quantifying Renin-Angiotensin-System Alterations in COVID-19. <i>Cells</i> , 2021, 10, 2755.	1.8	21
662	Endothelial dysfunction and COVID-19 (Review). <i>Biomedical Reports</i> , 2021, 15, 102.	0.9	7
663	Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 235-242.	0.9	10
664	Potential targets for preclinical diagnostics of acute kidney injury in covid-19 patients (review of) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 1	0.2	0
665	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	1.1	5

#	ARTICLE	IF	CITATIONS
666	A review on protective roles and potential mechanisms of metformin in diabetic patients diagnosed with COVID-19. <i>Metabolism Open</i> , 2021, 12, 100137.	1.4	5
667	Renal involvement in patients with COVID-19. <i>Clinics</i> , 2020, 75, e2194.	0.6	1
668	Therapeutic Approach to Coronavirus Disease. , 2020, , 67-97.		1
673	Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart. <i>Cardiac Failure Review</i> , 2020, 6, e18.	1.2	1
674	(Treatment with ACE inhibitors and AT1-blockers during the COVID-19 pandemic). <i>Cor Et Vasa</i> , 2020, 62, 27-32.	0.1	0
678	Renin-Angiotensin System inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID Pandemic. <i>Diabetes Epidemiology and Management</i> , 2021, 4, 100022.	0.4	1
679	Predictors of Mortality in Hospitalized COVID-19 Patients Complicated With Hypotension and Hypoxemia: A Retrospective Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 753035.	1.2	10
680	Association between prognostic factors and the outcomes of patients infected with SARS-CoV-2 harboring multiple spike protein mutations. <i>Scientific Reports</i> , 2021, 11, 21352.	1.6	10
681	Cardiovascular complications related to COVID-19 disease. <i>Anesthesia: Essays and Researches</i> , 2020, 14, 359.	0.2	2
682	COVID-19 Զ, Զ ^{3/4} Զ ^Զ ՆԶ»Զ,Ն,Զ _Զ »ՆԸԸ ^{1/2} Ն«Զ ¹ ՆՆ,ՆԸԶ _Զ ՆՆ. <i>Biochemistry</i> , 2020, 85, 1816-1828.	0.0	0
683	Should we recommend nonsteroidal anti-inflammatory drugs during the COVID-19 pandemic?. <i>ORL Ro</i> , 2020, 4, 46.	0.0	0
685	COVID-19 and the Cardiovascular System: A Review. <i>Wits Journal of Clinical Medicine</i> , 2020, 2, 157.	0.0	0
686	Cardiovascular diseases and complications in patients with COVID-19. <i>Profilakticheskaya Meditsina</i> , 2020, 23, 72.	0.2	1
687	Managing the Adult Congenital Heart Disease Patient in the COVID-19 Pandemic—A New York Perspective. <i>Congenital Heart Disease</i> , 2020, 15, 141-146.	0.0	2
689	RAAS Blockers and Region-Specific Variations in COVID-19 Outcomes: Findings from a Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
690	Neprilysin inhibitors and angiotensin(1â€“7) in COVID-19. <i>British Journal of Cardiology</i> , 2020, 27, 109-111.	0.7	3
691	Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1289-1297.	1.0	7
692	Risk of hospitalization and mortality associated with uncontrolled blood pressure in patients with hypertension and COVID-19. <i>International Journal of Cardiology Cardiovascular Risk and Prevention</i> , 2021, 11, 200117.	0.4	4

#	ARTICLE	IF	CITATIONS
694	Alamandine: Potential Protective Effects in SARS-CoV-2 Patients. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2021, 2021, 6824259.	1.0	5
695	Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation. Chemico-Biological Interactions, 2022, 351, 109738.	1.7	33
696	Comment on paper "the role of angiotensin-converting-enzyme 2 receptor in SARS-CoV-2 infections, and new perspective for future therapies. A brief review on recent literature". Italian Journal of Emergency Medicine, 2020, 9, .	0.0	0
698	Current and future use of angiotensin II receptor blockers in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 28-31.	0.2	0
699	Interim Guidance on the Preparticipation Physical Examination for Athletes During the SARS-CoV-2 Pandemic. Clinical Journal of Sport Medicine, 2021, 31, 1-6.	0.9	16
703	COVID-19 PANDEMÄ°SÄ°NDE NEFROLOJÄ° KLÄ°NÄ°KLERÄ°NÄ°N YÄ°NETÄ°MÄ°. NamÄ±k Kemal TÄ±p Dergisi, 0, , 0.0		0
707	Cessation of Renin-Angiotensin System Antagonists During the SARS-CoV-2 Pandemic â€“ Do We Have the Evidence?. Journal of Interdisciplinary Medicine, 2020, 5, 105-109.	0.1	0
708	COVID-19: a risk factor for fatal outcomes in patients with comorbid cardiovascular disease. Aging, 2020, 12, 18866-18877.	1.4	0
709	Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection. American Journal of Clinical and Experimental Immunology, 2020, 9, 73-80.	0.2	1
710	Prevalence, Clinical Manifestations, and Biochemical Data of Hypertensive versus Normotensive Symptomatic Patients with COVID-19: A Comparative Study. Acta Biomedica, 2020, 91, e2020164.	0.2	16
711	Medication use during COVID-19: Review of recent evidence. Canadian Family Physician, 2021, 67, 171-179.	0.1	1
713	Innovative diagnostic approach and investigation trends in COVID19-A systematic review. Journal of Oral and Maxillofacial Pathology, 2020, 24, 421-436.	0.3	1
715	Diabetes and Covid-19: Clinical implications and novel management strategies. Ulster Medical Journal, 2021, 90, 81-85.	0.2	0
716	Bidirectional Relationship between COVID-19 and Diabetes: Role of Renin-Angiotensin-Aldosterone System and Drugs Modulating It. Journal of Pharmacy and Bioallied Sciences, 2021, 13, 149-154.	0.2	0
717	To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients. EXCLI Journal, 2021, 20, 1145-1151.	0.5	1
718	Cardiovascular injuries and SARS-COV-2 infection: focus on elderly people. Journal of Geriatric Cardiology, 2021, 18, 534-548.	0.2	2
719	Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensin converting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients. Annals of Saudi Medicine, 2021, 41, 268-273.	0.5	0
721	Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensin converting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients. Annals of Saudi Medicine, 2021, 41, 268-273.	0.5	0

#	ARTICLE	IF	CITATIONS
722	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.6	6
723	COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme ² , Mutual Effects and Pharmacotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 772865.	1.5	15
724	Sex differences in the lung ACE/ACE2 balance in hypertensive rats. <i>Bioscience Reports</i> , 2021, 41, .	1.1	4
725	Understanding the role of nACE2 in neurogenic hypertension among COVID-19 patients. <i>Hypertension Research</i> , 2022, 45, 254-269.	1.5	10
727	ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. <i>Nature Communications</i> , 2021, 12, 6791.	5.8	32
728	No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 814-817.	0.7	2
729	Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. <i>BJPsych Open</i> , 2022, 8, e6.	0.3	33
730	Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 1-14.	1.0	26
731	Research Progress in the Treatment of Complications and Sequelae of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 757605.	1.2	9
732	Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 15.	0.8	16
733	Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 703661.	1.2	19
734	COVID-19: a risk factor for fatal outcomes in patients with comorbid cardiovascular disease. <i>Aging</i> , 2020, 12, 18866-18877.	1.4	1
735	VIII. Clinical Features of COVID-19 in the Aspects of Thrombus, Gerontology, and Therapeutics for Hypertension. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 2297-2300.	0.0	0
736	COVID-19 y su asociación con los IECA y ARAs. <i>Revista De La Facultad De Medicina, Universidad Nacional Autonoma De Mexico</i> , 2020, 63, 54-57.	0.0	0
737	Cardiovascular Burden of COVID-19 and the Post-Covid Era. , 2021, 1, 1-10.		0
738	Renin-Angiotensin-Aldosterone System. , 2021, , .		1
739	RAS and SARS-CoV-2 interaction: short review of the latest evidence. <i>Russian Journal of Infection and Immunity</i> , 2023, 13, 171-173.	0.2	0
741	Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems. <i>Journal of Clinical Medicine</i> , 2022, 11, 524.	1.0	73

#	ARTICLE	IF	CITATIONS
742	Association of renin-angiotensin-aldosterone system inhibition with COVID-19 hospitalization and all-cause mortality in the UK biobank. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2830-2842.	1.1	5
743	Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids. <i>IScience</i> , 2022, 25, 103818.	1.9	15
744	Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. <i>Medicina (Lithuania)</i> , 2022, 58, 144.	0.8	126
745	A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. <i>Pharmaceuticals</i> , 2022, 15, 78.	1.7	8
746	Sequelae and Comorbidities of COVID-19 Manifestations on the Cardiac and the Vascular Systems. <i>Frontiers in Physiology</i> , 2021, 12, 748972.	1.3	9
747	The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review. <i>International Journal of Hypertension</i> , 2022, 2022, 1-8.	0.5	7
748	The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 38-48.	1.1	3
749	Vitamin D Status and SARS-CoV-2 Infection in a Cohort of Kidney Transplanted Patients. <i>Nutrients</i> , 2022, 14, 317.	1.7	0
750	Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of COVID-19-Confirmed Cases and Deaths. <i>American Journal of Cardiology</i> , 2022, 165, 101-108.	0.7	4
751	Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19. <i>Cardiometabolic Syndrome Journal</i> , 0, 2, .	1.0	0
752	Association of Angiotensin Receptor Blockers With the Risk of COVID-19 in Korea. <i>Cardiometabolic Syndrome Journal</i> , 0, 2, .	1.0	1
753	Are angiotensin converting enzyme (ACE1/ACE2) gene variants associated with the clinical severity of COVID-19 pneumonia? A singlecenter cohort study. , 2022, 26, 133-140.		8
754	Tip of the iceberg: erectile dysfunction and COVID-19. <i>International Journal of Impotence Research</i> , 2022, 34, 152-157.	1.0	26
755	Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. <i>Cell Metabolism</i> , 2022, 34, 424-440.e7.	7.2	32
756	A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. <i>American Heart Journal</i> , 2022, 247, 76-89.	1.2	12
757	Fighting the pandemic with collaboration at heart: Report from cardiologists in a COVID-19-dedicated Portuguese intensive care unit. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 923-928.	0.2	1
758	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	1.8	27
760	ComunicaÃ§Ã£o em saÃºde sobre COVID-19 e Diabetes Mellitus em mÃ©dias sociais: verdadeiro e falso. <i>Escola Anna Nery</i> , 2022, 26, .	0.2	2

#	ARTICLE	IF	CITATIONS
761	Bihemispheric ischemic strokes in patients with COVID-19. <i>Brain Circulation</i> , 2022, 8, 10.	0.7	9
762	Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2911-2925.	2.0	0
763	Molecular and Physiological Aspects of SARS-CoV-2 Infection in Women and Pregnancy. <i>Frontiers in Global Women S Health</i> , 2022, 3, 756362.	1.1	1
764	Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2242.	1.8	17
765	Polycystic ovary syndrome and risks for COVID-19 infection: A comprehensive review. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 251-264.	2.6	9
766	Hypertension and COVID-19: Current Evidence and Perspectives. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 115-123.	1.0	44
767	COVID-19 Independent Risk Factors for Unfavorable Disease Progression: A Cross-Sectional Study from Romania. <i>International Journal of General Medicine</i> , 0, Volume 15, 2025-2036.	0.8	3
768	Propensity-Score-Matched Evaluation of Adverse Events Affecting Recovery after COVID-19 Vaccination: On Adenovirus and mRNA Vaccines. <i>Vaccines</i> , 2022, 10, 284.	2.1	4
769	Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment. <i>Biomedicines</i> , 2022, 10, 502.	1.4	10
770	Cardiorenal Disease in COVID-19 Patients. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2022, 2022, 4640788.	1.0	1
771	Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis. <i>Healthcare (Switzerland)</i> , 2022, 10, 645.	1.0	3
772	The Effects of Coronavirus on Human Health and Their Influence on Other Aspects of Life: A Scoping Review. <i>Biosciences, Biotechnology Research Asia</i> , 2022, 19, 47-68.	0.2	1
773	COVID-19-associated cardiac pathology at the postmortem evaluation: a collaborative systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1066-1075.	2.8	30
775	Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. <i>American Heart Journal</i> , 2022, 249, 86-97.	1.2	8
776	The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets. <i>Kidney International Supplements</i> , 2022, 12, 48-62.	4.6	10
777	Foe and friend in the COVID-19-associated acute kidney injury: an insight on intrarenal renin-angiotensin system. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1-11.	0.9	1
778	Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 792804.	1.1	1
779	SARS-CoV-2 and Implantation Window: Gene Expression Mapping of Human Endometrium and Preimplantation Embryo. <i>Life</i> , 2021, 11, 1378.	1.1	2

#	ARTICLE	IF	CITATIONS
780	Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients. <i>Journal of Hypertension</i> , 2022, 40, 666-674.	0.3	4
781	Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 397-406.	1.4	10
782	Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19. <i>Pathobiology</i> , 2022, 89, 166-177.	1.9	4
783	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2022, 118, 1618-1666.	1.8	32
784	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. <i>Journal of the American Heart Association</i> , 2021, 10, e023535.	1.6	15
785	Why Does the Severity of COVID-19 Differ With Age?. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, e36-e45.	1.1	49
786	Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19. <i>Drugs</i> , 2022, 82, 43-54.	4.9	7
787	Bad science in the time of COVID-19. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 434.	0.1	2
789	What is the association of renin-angiotensin-aldosterone system inhibitors with COVID-19 outcomes: retrospective study of racially diverse patients?. <i>BMJ Open</i> , 2022, 12, e053961.	0.8	1
790	Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients. <i>PLoS ONE</i> , 2022, 17, e0266922.	1.1	7
791	COVID-19 and kidney disease: insights from epidemiology to inform clinical practice. <i>Nature Reviews Nephrology</i> , 2022, 18, 485-498.	4.1	36
798	Transcriptional regulation and small compound targeting of ACE2 in lung epithelial cells. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2895-2904.	2.8	4
802	Pre-admission beta-blocker therapy and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2022, 22, .	0.2	1
803	Role of plasma angiotensin II and angiotensin-converting enzyme-2 levels on prognosis and mortality in hypertensive patients with COVID-19. <i>Biomarkers in Medicine</i> , 2021, 15, 1581-1588.	0.6	8
804	Innovative diagnostic approach and investigation trends in COVID-19-A systematic review. <i>Journal of Oral and Maxillofacial Pathology</i> , 2020, 24, 421.	0.3	2
805	Bidirectional relationship between covid-19 and diabetes: Role of renin-angiotensin-aldosterone system and drugs modulating it. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021, 13, 149.	0.2	1
806	Medication use during COVID-19. <i>Canadian Family Physician</i> , 2021, 67, 171-179.	0.1	6
807	Médicaments utilisés durant la COVID-19. <i>Canadian Family Physician</i> , 2021, 67, e69-e78.	0.1	0

#	ARTICLE	IF	CITATIONS
808	Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 315-323.	0.1	0
809	Safety of ACEi and ARB in COVID-19 management: A retrospective analysis. <i>Clinical Cardiology</i> , 2022, 45, 759-766.	0.7	9
810	Association between hypertension and prognosis of patients with COVID-19: A systematic review and meta-analysis. <i>Clinical and Experimental Hypertension</i> , 2022, 44, 451-458.	0.5	11
811	Predictors of Postacute Sequelae of COVID-19 Development and Rehabilitation: A Retrospective Study. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, 103, 2001-2008.	0.5	5
812	Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs. <i>Blood Pressure</i> , 2022, 31, 80-90.	0.7	4
813	Association of immediate reinsertion of new catheters with subsequent mortality among patients with suspected catheter infection: a cohort study. <i>Annals of Intensive Care</i> , 2022, 12, 38.	2.2	7
814	The effect of hypertension and antihypertensive therapies on the course of COVID-19 infection: Turkish national health system data. <i>Clinical and Experimental Hypertension</i> , 2022, , 1-5.	0.5	0
815	Evaluating the role of transthoracic echocardiography in hospitalised patients with COVID-19 infection. <i>Open Heart</i> , 2022, 9, e001854.	0.9	5
816	Plasma glucose levels and diabetes are independent predictors for mortality in patients with COVID-19. <i>Epidemiology and Infection</i> , 2022, 150, 1-26.	1.0	8
817	Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	12
818	p53/NF- κ B Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics). <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	18
819	COVID-19 and chronic kidney disease: peculiarities of treatment. <i>Ukrainian Journal of Nephrology and Dialysis</i> , 2022, , 83-89.	0.0	0
820	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19. <i>Journal of the American College of Cardiology</i> , 2022, , .	1.2	7
821	Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection. <i>Current Hypertension Reports</i> , 0, , .	1.5	8
822	Intrinsic Exercise Capacity Affects Glycine and Angiotensin-Converting Enzyme 2 (ACE2) Levels in Sedentary and Exercise Trained Rats. <i>Metabolites</i> , 2022, 12, 548.	1.3	2
823	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 0, .	0.9	5
824	The effect of renin-angiotensin-aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies. <i>Journal of Intensive Medicine</i> , 2022, 2, 282-290.	0.8	2
825	Interaction between Sars-CoV-2 structural proteins and host cellular receptors: From basic mechanisms to clinical perspectives. <i>Advances in Protein Chemistry and Structural Biology</i> , 2022, , 243-277.	1.0	4

#	ARTICLE	IF	CITATIONS
826	The prevalence and course of COVID-19 and the Cardiovascular Diseases. Heart Vessels and Transplantation, 0, .	0.0	0
828	Prevalence, Predictors, and Outcomes of Myocardial Injury in Hospitalized COVID-19 Patients—An Observational Retrospective Study. Hearts, 2022, 3, 66-75.	0.4	0
829	Hunting for protective drugs at the break of a pandemic: Causal inference from hospital data. Statistical Methods in Medical Research, 0, , 096228022210984.	0.7	0
830	Cardiovascular Implications of microRNAs in Coronavirus Disease 2019. Journal of Pharmacology and Experimental Therapeutics, 2023, 384, 102-108.	1.3	12
831	COVIDMED — An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients. Contemporary Clinical Trials Communications, 2022, 29, 100968.	0.5	5
833	An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine. Critical Pathways in Cardiology, 2022, 21, 123-129.	0.2	3
834	Proton Pump Inhibitors in the COVID-19 Pandemic. Russian Archives of Internal Medicine, 2022, 12, 245-253.	0.0	0
835	The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19. Irish Journal of Medical Science, 2023, 192, 1517-1523.	0.8	4
836	A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia. Cureus, 2022, , .	0.2	12
837	Coronavirus disease 2019, hypertension, and renin-angiotensin-aldosterone system inhibitors. Current Opinion in Cardiology, 2022, 37, 419-423.	0.8	1
838	Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research. Lancet Respiratory Medicine, the, 2022, 10, 900-915.	5.2	34
839	Lack of Correlation Between Soluble Angiotensin-Converting Enzyme 2 and Inflammatory Markers in Hospitalized COVID-19 Patients with Hypertension. Infection and Drug Resistance, 0, Volume 15, 4799-4807.	1.1	0
840	Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension. Journal of the American Heart Association, 2022, 11, .	1.6	26
841	Blood Pressure Control Among US Adults, 2009 to 2012 Through 2017 to 2020. Hypertension, 2022, 79, 1971-1980.	1.3	64
842	Epigenetic perspectives of COVID-19: Virus infection to disease progression and therapeutic control. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166527.	1.8	4
843	COVID-19 Impact on Host at Pathophysiological and Cellular Level. , 2022, , 67-111.		1
844	COVID-19 and Cardiovascular Manifestations. , 2022, , 102-136.		0

#	ARTICLE	IF	CITATIONS
845	COVID-19 and the heart. <i>British Medical Bulletin</i> , 2022, 144, 4-11.	2.7	5
846	The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 307.	0.8	5
847	Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-21.	2.4	6
848	COVID-19 Smell Impairment and Crosstalk with Hypoxia Physiology. <i>Life</i> , 2022, 12, 1408.	1.1	1
850	The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, .	1.1	22
851	Effects of a fixed nurse team in the orthopaedic surgery operating room on work efficiency and patient outcomes: a propensity score-matched historically controlled study. <i>BMC Nursing</i> , 2022, 21, .	0.9	2
852	Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. <i>Nature Communications</i> , 2022, 13, .	5.8	22
853	Adverse Cardiac Effects of SARS-CoV-2 Infection. , 0, 1, .		3
854	Antidiabetic treatment and COVID-19 Outcomes: A population-based cohort study in primary health care in Catalonia during the first wave of the pandemic. <i>Primary Care Diabetes</i> , 2022, 16, 753-759.	0.9	1
855	Effect of Comorbidities on the Infection Rate and Severity of COVID-19: Nationwide Cohort Study With Propensity Score Matching. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e35025.	1.2	2
856	Obesity, Diabetes Mellitus, and Metabolic Syndrome: Review in the Era of COVID-19. <i>Clinical Nutrition Research</i> , 2022, 11, 331.	0.5	2
857	Vaccination Against SARS-CoV-2 Protects from COVID-19-induced Endothelial Dysfunction. <i>Current Pharmaceutical Design</i> , 2022, 28, 3225-3230.	0.9	2
858	Impact of Hypertension on COVID-19 Burden in Kidney Transplant Recipients: An Observational Cohort Study. <i>Viruses</i> , 2022, 14, 2409.	1.5	2
859	Increased circulating microparticles contribute to severe infection and adverse outcomes of COVID-19 patients with diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 0, , .	1.5	0
860	COVID-19 outcomes in patients taking cardioprotective medications. <i>PLoS ONE</i> , 2022, 17, e0275787.	1.1	3
861	Use of chronic medications and risk of severe death due to COVID-19 in hospitalised patients. <i>European Journal of Hospital Pharmacy</i> , 0, , ejhpharm-2021-003186.	0.5	2
862	Postcovid syndrome, cardiovascular disorders. <i>Meditinskiy Sovet</i> , 2022, 16, 141-146.	0.1	1
863	Screening of Selected Stingless Bee Honey Varieties for ACE2-Spike Protein-Binding Inhibition Activity: A Potential Preventive Medicine Against SARS-Cov-2 Infection. <i>The Malaysian Journal of Medical Sciences</i> , 2022, 29, 146-153.	0.3	2

#	ARTICLE	IF	CITATIONS
864	Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101509.	1.1	5
865	Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank. <i>PLoS ONE</i> , 2022, 17, e0276781.	1.1	4
866	Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. <i>Biochemical Pharmacology</i> , 2023, 208, 115370.	2.0	7
867	Damage to the cardiovascular system and complications in Covid-19 infection with a focus on the post-acute covid19 syndrome. <i>Timocki Medicinski Glasnik</i> , 2022, 47, 104-118.	0.0	0
869	Does Previous Anti-thrombotic Use Affect the Course of Coronavirus Disease-2019?. <i>Ästanbul Medical Journal</i> , 2022, 23, 301-305.	0.1	0
870	Cardiovascular therapy use, modification, and in-hospital death in patients with COVID-19: A cohort study. <i>PLoS ONE</i> , 2022, 17, e0277653.	1.1	0
872	Identification and mechanistic basis of non-ACE2 blocking neutralizing antibodies from COVID-19 patients with deep RNA sequencing and molecular dynamics simulations. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
874	COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19. <i>Hypertension Research</i> , 2023, 46, 589-600.	1.5	14
875	Angiotensin-Converting Enzyme (ACE) Inhibitors May Moderate COVID-19 Hyperinflammatory Response: An Observational Study with Deep Immunophenotyping. <i>Health Data Science</i> , 2022, 2022, .	1.1	4
876	COVID-19 and Antihypertensive Treatment. <i>Contemporary Cardiology</i> , 2022, , 303-316.	0.0	0
877	Renin-Angiotensin-Aldosterone axis inhibition improves outcome of diabetic patients with chronic hypertension and COVID-19: An Iranian perspective. <i>Advanced Biomedical Research</i> , 2022, 11, 109.	0.2	0
878	Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19. <i>PLoS ONE</i> , 2023, 18, e0280280.	1.1	9
879	Lithium treatment extends human lifespan: findings from the UK Biobank. <i>Aging</i> , 2022, 15, 421-440.	1.4	6
880	Endothelial dysfunction in patients with COVID-19 is a key mechanism for the development of complications. <i>Systemic Hypertension</i> , 2023, 19, 37-44.	0.1	1
881	The mechanism of low-level arsenic exposure-induced hypertension: Inhibition of the activity of the angiotensin-converting enzyme 2. <i>Chemosphere</i> , 2023, 318, 137911.	4.2	5
882	Using Decision Trees as an Expert System for Clinical Decision Support for COVID-19. <i>Interactive Journal of Medical Research</i> , 0, 12, e42540.	0.6	4
884	The effect of COVID-19 on the in-hospital outcomes of percutaneous coronary intervention in patients with acute coronary syndrome: A large scale meta-analysis. , 2023, 9, 100032.		1
885	Links between COVID-19 and Parkinsonâ€™s disease/Alzheimerâ€™s disease: reciprocal impacts, medical care strategies and underlying mechanisms. <i>Translational Neurodegeneration</i> , 2023, 12, .	3.6	15

#	ARTICLE	IF	CITATIONS
886	Primary Aldosteronism and COVID-19-related Management, Disease Severity, and Outcomes: A Retrospective Cohort Study. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.1	1
887	SARS-CoV-2 and microbiome. , 2023, , 279-337.		0
888	Recognizing risk factors associated with poor outcomes among patients with COVID-19. <i>Progress in Cardiovascular Diseases</i> , 2023, 76, 3-11.	1.6	6
889	Relationship between severe acute respiratory syndrome coronavirus 2 and diabetes mellitus (review). <i>Diabetes Mellitus</i> , 2023, 26, 66-74.	0.5	0
890	Risk of Underlying Diseases and Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in Japan: Retrospective Observational Study. <i>International Journal of General Medicine</i> , 0, Volume 16, 657-672.	0.8	2
891	Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection. <i>Nature Genetics</i> , 2023, 55, 471-483.	9.4	14
893	A machine learning analysis of correlates of mortality among patients hospitalized with COVID-19. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
894	BCG Vaccination of Health Care Workers Does Not Reduce SARS-CoV-2 Infections nor Infection Severity or Duration: a Randomized Placebo-Controlled Trial. <i>MBio</i> , 2023, 14, .	1.8	12
895	Clinical and social determinants of health features of SARS-CoV-2 infection among Black and Caribbean Hispanic patients with heart failure: The SCAN-MP Study. <i>PLoS ONE</i> , 2023, 18, e0283730.	1.1	0
896	COVID-19 and the Cardiovascular System. , 2024, , 137-158.		0
897	Post-Exposure Prophylaxis for COVID-19: A Systematic Review. <i>Infectious Disorders - Drug Targets</i> , 2023, 23, .	0.4	1
918	A Review of Statins and COVID-19. , 0, , .		0
919	Mitigating secondary disaster triggered by fear of COVID-19: the role of professional medical societies. <i>Hypertension Research</i> , 2024, 47, 559-561.	1.5	0
922	Pharmacotherapeutics for cytokine storm in COVID-19. , 2024, , 101-125.		0